Clinical Research Trials

Clinical research trials are an integral part of the advancement in medicine for both the treatment and prevention of infectious diseases. These trials serve to discover whether or not a particular treatment or preventative is safe and effective. All new drugs and medical devices must go through the process of clinical trials before being approved, produced, and marketed for the general public; thus, it is ultimately our volunteers whom help us understand, prevent, and treat communicable diseases.

A common misconception about clinical research trials is that only people who are sick or have a disease participate in them. Clinical trials, however, need people from all types of backgrounds for studies, including those who are healthy and those who have an illness or disease. Healthy people may choose to participate because they know someone who is affected by a particular illness or disease, or they may participate for philanthropic reasons. Participants who are sick or have a disease may also want to help others; however, being in a clinical research trial provides them with a chance to receive a new treatment as well as additional medical care and attention specifically for their ailment.

No matter the reason for joining a clinical research trial, just remember: With your help, we can bring an end to many infectious diseases throughout the world! Be the change...

Click below to view our upcoming and currently enrolling research studies. For a printable Clinical Research Trial Guide, click here.

Bavarian Nordic RSV is anticipated to be a Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of the Recobinant MVA-BN RSV vaccine after intranasal and intramuscular administration. RSV: Respiratory Syncytical Virus

Eligibility criteria has not yet been determined and will be updated as received.

If interested in placement on the wait-list for this study, please contact us via phone or the web.

The Flu Vaccine study is a Phase II study assessing safety, reactogenicity, and immunogenicity of a Sanofi Pasteur A/H7N9 inactivated Influenza vaccine administered intramuscularly with or without AS03 adjuvant.

This study is open to healthy, HIV-negative adults aged 19 to 64 years old. Females able to become pregnant must be willing to use a medically accepted contraceptive method from 30 days before first vaccination until 60 days after the last study vaccination. Participation in this study will last approximately 13 months with up to 8 scheduled clinic visits and 2-7 phone calls depending on which group you are randomized into.

Other inclusion criteria applies. Compensation is provided after enrollment for those who qualify. This study will enroll rapidly over a 12 week period once open. If interested in participating, it is recommended that you contact us immediately to be placed on the wait-list for eligibility screening.

For more information or to be placed on the wait-list for this study, please contact us via phone or the web.

HVTN 125 is a Phase Ib randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of the IHV01 protein vaccine primed and co-administered with HIV DNA CON-S env vaccine in healthy, HIV-1-uninfected adults. Additional information is not available at this time. Please check back later for updates and eligibility criteria.

Researchers are interested in developing a rectal product to protect against HIV infection during anal sex. This study is being done to see what kinds of products people would prefer to use before anal sex— a douche, an insert, or a suppository. Participants will be asked to use each product for a period of 1 month and complete surveys about their opinion and experiences with each one. There is no active drug in any of the products being used. The study lasts about 3 months, and involves a total of 8 visits. You will be compensated for your time.

.

For more information or to see if you are eligible for this study, please contact us via phone or the web.

The purpose of the study is to test the safety and acceptability of a new rectal gel, which is being developed to protect against HIV infection during anal sex. If you are HIV negative and have had anal sex at least once in your life, you may be eligible to participate. The study involves 9 visits over a period of about 3-5 months. During this time, participants will insert the gel, rectally, a total of 3 times. Rectal biopsies will be collected at 5 of the visits. You will be compensated for your time.

.

For more information or to see if you are eligible for this study, please contact us via phone or the web.

Reprieve is an AIDS Clinical Trial Group (ACTG) study for HIV positive men and women between the ages of 40 and 75. The purpose of this study is to see if pitavastatin, an FDA-approved drug for the treatment of high cholesterol, can prevent heart disease and heart disease related deaths in people with HIV infection who are also taking HIV medications.

To be eligible for this study, you must meet the age and HIV-status requirements, and you must also have been on antiretroviral therapy (ART) for at least six months prior to study entry. Women of childbearing potential must not be pregnant and agree not to participate in the conception process.

Those with a history of heart disease, current use of a -statin drug, or with a history of cancer within the past three years will not qualify. Additional exclusion criteria applies.

Compensation is provided after enrollment for those who qualify. If interested, please be aware that you will be in this study for up to six years. You will need to be seen in clinic for a screening visit, an entry visit, one month later, and then every four months.

For more information or to see if you qualify, contact us via phone or the web.

This study is open to HIV-negative cisgender (men who were born male and identify as male) men and transgender women who have sex with men and who are aged 18 or older. Participation in this study will last approximately 4 years with about 57 visits to the clinic.

For more information or to see if you are eligible for this study, please contact us via phone or the web.